SparsePro: an efficient genome-wide fine-mapping method integrating summary statistics and functional annotations

3

9

10

11

12

13

15

16

17

18

19

Wenmin Zhang¹, Hamed Najafabadi^{1,2,3}, and Yue Li^{1,4,*}

¹Quantitative Life Sciences, McGill University, Montreal, Canada

²Department of Human Genetics, McGill University, Montreal, Canada

³McGill Genome Centre, Montreal, Canada

⁴School of Computer Science, McGill University, Montreal, Canada;

*Correspondence to yueli@cs.mcgill.ca

Abstract

Identifying causal variants from genome-wide association studies (GWASs) is challenging due to widespread linkage disequilibrium (LD). Functional annotations of the genome may help prioritize variants that are biologically relevant and thus improve fine-mapping of GWAS results. However, classical fine-mapping methods have a high computational cost, particularly when the underlying genetic architecture and LD patterns are complex. Here, we propose a novel approach, SparsePro, to efficiently conduct functionally informed statistical fine-mapping. Our method enjoys two major innovations: First, by creating a sparse low-dimensional projection of the high-dimensional genotype data, we enable a linear search of causal variants instead of a combinatorial search of causal configurations used in most

existing methods; Second, we adopt a probabilistic framework with a highly efficient variational expectation-maximization algorithm to integrate statistical associations and functional priors. We evaluate SparsePro through extensive simulations using resources from the UK Biobank. Compared to state-of-the-art methods, SparsePro achieved more accurate and well-calibrated posterior inference with greatly reduced computation time. We demonstrate the utility of SparsePro by investigating the genetic architecture of five functional biomarkers of vital organs. We show that, compared to other methods, the causal variants identified by SparsePro are highly enriched for expression quantitative trait loci and explain a larger proportion of trait heritability. We also identify potential causal variants contributing to the genetically encoded coordination mechanisms between vital organs, and pinpoint target genes with potential pleiotropic effects. In summary, we have developed an efficient genome-wide fine-mapping method with the ability to integrate functional annotations. Our method may have wide utility in understanding the genetics of complex traits as well as in increasing the yield of functional follow-up studies of GWASs. SparsePro software is available on GitHub at https://github.com/zhwm/SparsePro.

1 Introduction

42 8].

- Establishment of large biobanks and advances in genotyping and sequencing technologies
 have enabled large-scale genome-wide association studies (GWASs) [1–3]. Although GWASs
 have revealed extensive associations between genetic variants and traits of interest, understanding the genetic architecture underlying these genetic associations remains challenging
 [4–6], mainly because GWASs typically rely on univariate regression models, which are not
 able to distinguish the causal variants from other variants in linkage disequilibrium (LD) [5, 7,
- Several statistical fine-mapping approaches have been proposed for identifying causal variants in GWASs while considering the underlying LD patterns. For instance, BIMBAM [9], CAVIAR [10] and CAVIARBF [11] estimate the posterior inclusion probabilities (PIPs) in a pre-defined locus by evaluating multivariate Gaussian likelihood enumerating all possible configurations.

FINEMAP [12] accelerates the inference with a shotgun stochastic search focusing on the most likely subset of causal configurations. However, the number of causal configurations required 48 to evaluate can grow combinatorially as the number of causal variants increases, thus tremen-49 dously increasing the computational cost if multiple causal variants exist. SuSiE [13] introduces 50 an iterative Bayesian stepwise selection algorithm for variable selection, which can also be ap-51 plied to statistical fine-mapping with greatly improved computational efficiency. 52 Furthermore, it has been recognized that functional annotations of the genome may help pri-53 oritize variants that are biologically relevant, thus improving fine-mapping of GWAS results [8]. For example, PAINTOR [14] and RiVIERA [15] empirically estimate the impacts of functional 55 annotations from statistical evidence, which improves the accuracy of fine-mapping but has a high computational cost, especially when multiple causal SNPs exist in the same locus. Poly-Fun [16] adopts stratified LD score regression [17] to effectively partition total trait heritability into annotation-dependent heritability estimates, and uses these estimates of annotationtagged heritability to specify functional priors for fine-mapping methods. 60 In this work, we present a unified probabilistic framework called Sparse Projections to Causal Effects (SparsePro) for statistical fine-mapping with the capacity to incorporate functional annotations. Accompanied with an efficient variational expectation-maximization inference algorithm [18], SparsePro achieves superior accuracy in identifying causal variants as well as computa-64 tional efficiency compared to the state-of-the-art approaches in both simulation studies and real 65 data analyses. We further demonstrate the utility of SparsePro in genome-wide fine-mapping of 66 functional biomarkers for five vital organs in human. 67

2 Materials and Methods

2.1 SparsePro method overview

To fine-map causal SNPs, our method takes two lines of evidence (**Figure** 1). First, from estimated marginal associations between genetic variants and a complex trait of interest, accompanied by matched LD information, we can group correlated genetic variants together and assess their effects jointly. Then, we infer the contribution of each SNP towards each group of causal effect separately to obtain posterior inclusion probabilities (PIPs). Second, optionally, if we have knowledge about any functional annotations which may be enriched for the causal SNPs, we can estimate the relative enrichment of these annotations, and re-prioritize SNPs according to the enrichments of these annotations. As outputs, our model yields functionally informed PIP for each SNP and the enrichment estimates of candidate functional annotations.

2.2 Our contributions in the context of the existing methods

Our work is related to two existing methods, SuSiE [13] and PolyFun [16]. Inspired by the "sum of single effects" model in SuSiE, we introduce a sparse projection of the genotype in our model 81 specification so that the identification of causal variants and estimation of causal effect sizes are separated. This sparse projection avoids exhaustively evaluating the combinatorial num-83 ber of causal configurations. For statistical inference, SuSiE adopts an iterative Bayesian step-84 wise selection algorithm that operates on the Bayes Factors (BFs) [13]. Here, we use a paired 85 mean field variational inference algorithm [18] to jointly update the variational parameters for 86 the causal effects and causal indicators of each SNP. Moreover, we have adapted our algorithm 87 to directly work with GWAS summary statistics and provided appropriate estimates for the hy-88 perparamters including trait variance and heritability estimates. To enable functionally informed fine-mapping, PolyFun uses genome-wide heritability estimates from LD score regression to 90 set the functional priors for fine-mapping methods [16]. In contrast, we aggregate the genome-91 wide statistical fine-mapping evidence by maximizing the evidence lower bound of SparsePro to prioritize relevant annotations and robustly derive genome-wide functional priors.

2.3 SparsePro model specification

We assume the following data generative process (**Figure** 1) for a continuous polygenic trait. First, the prior probability $\tilde{\pi}_g$ for the g-th SNP ($g \in \{1, \dots, G\}$) being causal is defined as:

$$\tilde{\pi}_g = softmax(\mathbf{A}_g \mathbf{w}) = \frac{\exp(\mathbf{A}_g \mathbf{w})}{\sum_{g'=1}^{G} \exp(\mathbf{A}_{g'} \mathbf{w})}$$

where \mathbf{A}_g is the 1 imes M annotation row vector of M candidate annotations for the g-th SNP; and

- \mathbf{w} is the M imes 1 vector of logarithm of relative enrichment. Here, we use the softmax function
- ₉₇ to ensure the prior probabilities sum up to 1. If no functional information is provided, the prior
- probability of being causal is considered equal for all SNPs, i.e. $ilde{\pi}_g=rac{1}{G}.$

We assume that there exist K independent causal effects, and that

$$\mathbf{s}_k \sim Multinomial(1, \tilde{\boldsymbol{\pi}})$$

where $\tilde{\pi} = (\tilde{\pi}_1, ..., \tilde{\pi}_G)$ and \mathbf{s}_k is a binary indicator vector of length G indicating which SNP is the causal SNP under the k-th ($k \in \{1, ..., K\}$) causal effect.

Then, the causal effect sizes are sampled from a normal distribution, i.e.

$$\beta_k \sim \mathcal{N}(0, \tau_{\beta_k}^{-1})$$

Finally, the continuous trait $y_{N\times 1}$ over N individuals is generated as follows:

$$\mathbf{y} = \mathbf{X} \sum_k \mathbf{s}_k eta_k + \mathbf{\epsilon}$$

or in matrix form:

$$y = XS\beta + \varepsilon$$

where $\mathbf{X}_{N \times G}$ is the full genotype matrix, $\mathbf{S}_{G \times K}$ is the sparse projection matrix, $\boldsymbol{\beta}_{K \times 1}$ is the causal effect vector, and $\boldsymbol{\epsilon}_{N \times 1} \sim \mathcal{N}(0, \tau_y^{-1} \mathbf{I}_N)$ denotes the variance not attributable to the modelled ge-

os netic effects.

2.4 A variational inference algorithm for Bayesian fine-mapping

With this model specification (**Figure** 1), finding the causal variants is equivalent to inferring the sparse projections s_k and the effect sizes β_k given y and X for $k \in \{1, ..., K\}$:

$$p(\mathbf{S}, \boldsymbol{\beta} | \mathbf{y}, \mathbf{X}, \tilde{\boldsymbol{\pi}}, \tau_{\beta}, \tau_{y}) = \frac{p(\mathbf{y}, \mathbf{S}, \boldsymbol{\beta} | \mathbf{X}, \tilde{\boldsymbol{\pi}}, \tau_{\beta}, \tau_{y})}{p(\mathbf{y} | \mathbf{X}, \tilde{\boldsymbol{\pi}}, \tau_{\beta}, \tau_{y})}$$

As the number of possible causal configurations grows combinatorial with G, the exact posterior solution is intractable because of the marginal likelihood in the denominator. Unlike most existing fine-mapping approaches using sampling-based methods to search through a subset of possible causal configurations [12, 19], we adopt a paired mean field factorization of variational family to approximate the posterior [18]:

$$q(\mathbf{S}, \boldsymbol{\beta}) = \prod_{k} q(\mathbf{s}_{k}, \beta_{k}) = \prod_{k} q(\mathbf{s}_{k}) q(\beta_{k} | \mathbf{s}_{k})$$

This variational distribution preserves the dependency between s_k and β_k . It has been shown that the paired mean field variational family has similar mode and shape as the desired posterior distribution, and that such inference can achieve high accuracy with substantially improved computational efficiency [18].

To find the best approximation, we minimize the Kullback-Leibler (KL) divergence between the posterior distribution and the proposed variational distribution, which is equivalent to maximizing the evidence lower bound (ELBO) [20]:

$$ELBO = E_q[\log p(\mathbf{y}, \mathbf{S}, \boldsymbol{\beta} | \mathbf{X}, \tilde{\boldsymbol{\pi}}, \tau_{\beta}, \tau_y)] - E_q[\log q(\mathbf{S}, \boldsymbol{\beta})]$$

Based on the mean field assumptions [18], this optimization can be conducted iteratively for the k^{th} causal effect and the g^{th} SNP with the following closed-form updates until convergence (derivation details are available in **Supplementary Notes**). We update posterior effect size for the g-th SNPs in the k-th causal effect:

$$\mu_{kg}^* = \frac{\tau_y}{\tau_{kg}^*} (\mathbf{X}_g^\top \mathbf{y} - \mathbf{X}_g^\top \mathbf{X} \sum_{k' \neq k} \mathbf{\gamma}_{k'}^* \circ \mathbf{\mu}_{k'}^*)$$
 (1)

113 with

112

$$\tau_{kq}^* = \mathbf{X}_q^{\mathsf{T}} \mathbf{X}_g \tau_y + \tau_{\beta_k} \tag{2}$$

where o represents element-wise multiplication of vectors.

We then update the posterior probability of the g-th SNP being causal in the k-th causal effect:

$$\gamma_{kg}^* = softmax(\log \tilde{\pi}_g - \frac{1}{2} \log \frac{\tau_{kg}^*}{2\pi} + \frac{\tau_{kg}^* \mu_{kg}^{*2}}{2})$$
 (3)

For fine-mapping, we take the maximum of these K probabilities as the PIP for SNP g: $\gamma_g^* = \max(\gamma_{1g}^*, \dots, \gamma_{Kg}^*)$.

2.5 Adaptation to GWAS summary statistics

The above variational inference algorithm requires access to large datasets containing both individual-level genotype X and phenotype data y. Since a growing number of GWASs have released publicly available summary statistics (i.e., marginal effect size estimate $\hat{\beta}_g$ and its standard error se_g for the g-th SNP), we adapt SparsePro to directly operate on these summary statistics with additional information from an LD reference panel (i.e. estimates of pairwise SNP-SNP Pearson correlation).

Specifically, if we have reasonable surrogates for $X_a^T X_g$, $X^T X$ and $X_a^T y$, we can plug them

Specifically, if we have reasonable surrogates for $\mathbf{X}_g^{\top}\mathbf{X}_g$, $\mathbf{X}^{\top}\mathbf{X}$ and $\mathbf{X}_g^{\top}\mathbf{y}$, we can plug them into Equations (1), (2), and (3). We include two forms of reformulation depending on whether the genotypes are standardized to have zero mean and unit variance in the GWAS.

1. If the genotypes are standardized, we have

$$\mathbf{X}_q^{\top}\mathbf{X}_g = N$$

$$\mathbf{X}^{\top}\mathbf{X} = N * LD$$

$$\mathbf{X}_g^{\top} \mathbf{y} = N \hat{\beta}_g$$

where N is the sample size.

2. If the genotypes are not standardized, we have

$$\hat{\beta}_g = (\mathbf{X}_g^{\top} \mathbf{X}_g)^{-1} \mathbf{X}_g^{\top} \mathbf{y}$$

$$se_g = \sqrt{var(\mathbf{y})(\mathbf{X}_g^{\top}\mathbf{X}_g)^{-1}}$$

Therefore,

129

130

131

132

133

$$\mathbf{X}_g^{\top} \mathbf{X}_g = \frac{var(\mathbf{y})}{(se_g^2)}$$

$$\mathbf{X}^{\top}\mathbf{X} = LD * (\mathbf{se}^{\top}\mathbf{se})$$

$$\mathbf{X}_g^{\top}\mathbf{y} = \mathbf{X}_g^{\top}\mathbf{X}_g * \hat{\beta}_g$$

Notably, if \mathbf{y} has been standardized to have unit variance prior to a GWAS, we naturally supply $var(\mathbf{y}) = 1$. Otherwise, it can be estimated as $var(\mathbf{y}) = 2Np(1-p)se^2$ where N (the study sample size), p (minor allele frequencies), and se (standard errors of effect size estimates) are usually available in GWAS summary statistics.

2.6 Variational expectation-maximization for integrating functional annotations

To estimate the relative enrichment of functional annotations and further prioritize variants, we adopt a variational expectation-maximization scheme to maximize ELBO with respect to the logarithm of relative enrichment (\mathbf{w}) first and then use the estimate $\hat{\mathbf{w}}$ to calculate $\tilde{\pi}_g$ (prior probability of being causal) for each SNP.

Suppose we have M candidate annotations and A_{gm} ($m \in \{1,...,M\}$) is a 0/1 indicator denoting whether the g-th SNP has the m-th annotation. By setting the derivative of ELBO with respect to w_m to 0 and solving for w_m , we have the following estimate for the logarithm of rele-

vant enrichment (detailed in Supplementary Notes),

$$w_m = \log(\frac{r_1/r_0}{k_1/k_0})$$

where

$$k_{1} = \sum_{g} [A_{gm} = 1] softmax(\sum_{m' \neq m} A_{gm'} w_{m'})$$

$$k_{0} = \sum_{g} [A_{gm} = 0] softmax(\sum_{m' \neq m} A_{gm'} w_{m'})$$

$$r_{1} = \sum_{k,g} [A_{gm} = 1] \gamma_{kg}^{*}$$

$$r_{0} = \sum_{k,g} [A_{gm} = 0] \gamma_{kg}^{*}$$

We note that this metric is equivalent to the logarithm of a relative risk, thus its standard error can be calculated as

$$se(w_m) = \sqrt{\frac{1}{r_1} + \frac{1}{r_0} - \frac{1}{k_1} - \frac{1}{k_0}}$$

We evaluate the significance of annotation enrichment with the log likelihood ratio test (G-test) [21]. Only annotations which demonstrate statistical significance are included in our model to update the prior probability of being causal for each SNP. Specifically,

$$\tilde{\pi}_g = softmax(\sum_m A_{gm}\hat{w}_m)$$

This functionally informed prior helps prioritize causal SNPs in addition to statistical evidence.

2.7 Hyperparameter settings

We have three hyperparameters: number of causal effect K, inverse of the unexplained variance τ_y and inverse variance of causal effect sizes τ_{β_k} in our model. As we show in **Supplementary Notes**, our model is not sensitive to the setting of K as long as K is larger than the

actual number of independent effects, except that increasing K marginally increases the computation time.

We set τ_u as

147

$$\tau_y = \frac{1}{var(y) * (1 - h^2)}$$

where h^2 is the local SNP heritability that can be estimated by a modified Heritability Estimation from Summary Statistics (HESS) [22] based on GWAS summary statistics (**Supplementary** Notes)

We set τ_{β} as

$$\tau_{\beta} = \frac{k}{var(y) * h^2}$$

for each of the independent causal effects. We use $k \in \{1, ..., K\}$ to account for different effect sizes and to improve model identifiability.

4 2.8 Simulation studies

We conducted simulations to showcase the efficiency and utility of our method. We leveraged 155 resources from the UK Biobank [1]. Specifically, we first retained 353,606 White British an-156 cestry participants by excluding one individual from each pair of closely related individuals 157 (who had a 3rd degree or closer relationship). We then retrieved the genotypes of these indi-158 viduals based on 271,699 SNPs which had a minor allele frequency > 0.001 and an imputation quality score > 0.6 on chromosome 22. Next, we sampled 50 causal SNPs with a twofold relative enrichment amongst SNPs that were annotated as "conserved sequences" [23], "DNase I hypersensitive sites" (DHS) [24], "non-synonymous" [25], or that overlapped with histone marks H3K27ac [26] or H3K4me3 [24]. We used the GCTA GWAS simulation pipeline [27] to simulate a continuous trait with a per-chromosome heritability of 0.01. We tested the associ-164 ation between each SNP and this simulated trait, and obtained GWAS summary statistics using 165 the fastGWA software [28]. This process was replicated 22 times to imitate a GWAS. We obtained LD information calculated using the UK Biobank participants from https://alkesgroup.
broadinstitute.org/UKBB_LD/ [16]. These LD matrices were generated for genome-wide
SNPs binned into sliding windows of 3 Mb where two neighboring windows had a 2-Mb overlap.

We applied SparsePro to the GWAS summary statistics with the above LD information, and 171 iterated over all sliding windows, first without any functional annotation information. We de-172 noted the fine-mapping results as "SparsePro-". Next, we aggregated the results from all 22 173 replications to estimate the relative enrichment for ten binary functional annotations. In addition 174 to the five annotations simulated to be enriched of causal SNPs, we also included five anno-175 tations without enrichment: "actively transcribed regions" [29], "transcription start sites" [29], 176 'promoter regions" [30], "5'-untranslated regions" [25], and "3'-untranslated regions" [25]. 177 Annotations with a G-test p-value $< 1 \times 10^{-6}$ were selected to conduct functionally informed 178 fine-mapping, and the results were denoted as "SparsePro+". τ_{β} and τ_{y} were set according to aforementioned empirical estimates. PIPs for SNPs in the 1-Mb centre of each 3-Mb sliding 180 window were extracted.

2.9 Method comparisons using simulated data

We also performed fine-mapping with some of the state-of-the-art methods. To perform finemapping with conditional and joint (COJO) analyses [31] and FINEMAP [12], we first selected

COJO lead SNPs based on GWAS summary statistics by performing stepwise model selection implemented in the GCTA-COJO software [27]. We then applied FINEMAP with shotgun
stochastic search to SNPs in a 1-MB window centered at each COJO-identified lead SNP. We
wrote an in-house script using the "susie_rss" function to perform genome-wide fine-mapping
with SuSiE in the same sliding windows as SparsePro. We aggregated summary statistics from
22 replications and used PolyFun with the "baselineLF2.2.UKB" model [16] to calculate functional priors. The "baselineLF2.2.UKB" model contained all annotations used in SparsePro as
well as additional pre-computed LD-related annotations for optimal performance of PolyFun

[16]. The estimated priors were provided to SuSiE via "prior_weights" and to FINEMAP via the

--prior-snps option, respectively. The maximal number of causal SNPs in each locus was set to 5 for all methods.

We compared the performance of these methods in terms of precision (1 - false discovery rate), recall, calibration of PIPs, as well as computation time, all evaluated on a 2.1 GHz CPU node on Compute Canada.

2.10 Fine-mapping genetic determinants of functional biomarkers for vital organs

200

To investigate the genetic coordination mechanisms of vital organs, we performed GWAS in 201 the UK Biobank [1] for five functional biomarkers: forced expiratory volume in one second to 202 forced vital capacity (FEV1-FVC) ratio for lung function, estimated glomerular filtration rate for 203 kidney function, pulse rate for heart function, total protein for liver function and blood glucose 204 level for pancreatic islet function. For each trait, we first regressed out the effects of age, age², 205 sex, genotyping array, recruitment centre, and the first 20 genetic principal components before 206 inverse normal transforming the residuals to z-scores that had zero mean and unit variance. 207 We then performed GWAS analysis on the resulting z-scores with the fastGWA software [27, 208 28] to obtain summary statistics. 209

Using the summary statistics and the matched LD information [16], we performed genomewide fine-mapping with SparsePro-, SparsePro+, SuSiE and PolyFun-informed SuSiE as described in the simulation analyses (**Section** 2.9), except that the number of causal effects was
set to 9 for each LD region to account for potentially more causal variants.

To evaluate the biological relevance of SNPs fine-mapped by different methods, we assessed their relative enrichment in tissue-specific expression quantitative loci (eQTL). Tissue-specific eQTL identified in the most recent release of the Genotype-Tissue Expression (GTEx) project [32, 33] were obtained from https://gtexportal.org/home/datasets. The eQTL information was not used by any functionally informed fine-mapping methods.

Additionally, we calculated trait heritability conferred by fine-mapped SNPs with SparseProand SparsePro+, respectively, at several commonly used PIP thresholds for determining causal

variants: 0.50, 0.80, 0.90, 0.95, and 0.99. The adjusted R^2 obtained from multivariate linear re-221 gression of the z-scores (i.e. inverse normal transformed trait residuals after regressing out co-222 variate effects) against all fine-mapped SNPs was used as a surrogate of the SNP heritability. 223 We compared these results to heritability captured by the same number of SNPs fine-mapped 224 by SuSiE and PolyFun-informed SuSiE, separately at each PIP threshold. For instance, if SparsePro-225 identified J SNPs with a PIP > 0.5, we would select J SNPs with the highest PIP determined 226 by SuSiE and compare the adjusted R^2 . Notably, this analysis evaluates predictive associations 227 instead of actual causality, hence the adjusted R^2 is not a direct indicator of the validity of the 228 fine-mapping results. 229 We selected SNPs with a PIP > 0.8 to explore possible pleiotropic effects using phenogram 230

[34]. Loci with potential pleiotropic effects were visualized using LocusZoom [35].

3 Results

3.1 SparsePro demonstrates superior performance in simulation

We performed simulations based on real genotype data from UK Biobank (Materials and Meth-234 **ods**). We observed that SparsePro consistently demonstrated superior accuracy in identify-235 ing true causal variants. SparsePro without annotation (SparsePro-) achieved an area under 236 the precision-recall curve (AUPRC) of 0.3699, higher than the AUPRC of 0.2677 by FINEMAP 237 and the AUPRC of 0.3573 by SuSiE (Figure 2A). Notably, SparsePro had a substantially higher 238 precision at the same recall rates (Figure 2A). For example, at the recall rate of 25%, Sparse-239 Pro achieved greater than 95% precision, which is highly desirable in fine-mapping because only a small number of the prioritized SNPs will be experimented validated in vivo or in vitro in practice (Figure 2A). 242 Moreover, SparsePro can incorporate functional priors (Supplementary Table S1) with im-243 proved fine-mapping power. SparsePro+ achieved an AUPRC of 0.4636, outperforming both 244 functionally informed FINEMAP (AUPRC = 0.3088) and functionally informed SuSiE (AUPRC 245 = 0.4042) with functional priors derived by PolyFun. As expected, we also found that the per-246 formance of SparsePro was not sensitive to the pre-specified number of independent causal 247 effects (Supplementary Table S2 and Supplementary Notes). 248 Compared to FINEMAP and SuSiE, the PIPs yielded by SparsePro appeared to be much 249 more calibrated. It has been shown that for a well-calibrated fine-mapping method, the mean 250 PIP of all SNPs with a PIP above a certain threshold should be equal to the precision if these 251 SNPs were to be considered causal variants [16]. Here, we found that the mean PIP of all SNPs 252 considered to be causal variants by SparsePro was almost identical to the desired precision at 253 any threshold (Figure 2B). In contrast, the PIPs generated by FINEMAP and SuSiE appeared 254 to be inflated (Figure 2B). 255 For instance, if SNPs with a PIP > 0.8 were to be considered as causal variants, SparsePro-256 and SparsePro+ would both have a median precision across simulations of 95% and 100% 257

respectively (Figure 2C). The selected SNPs by FINEMAP (median precision = 50% only)

and SuSiE (median precision = 71% only) included an excessive proportion of false positives, 259 even with functional priors (median precision = 77% for FINEMAP and 79% for SuSiE; Fig-260 ure 2C). The high precision by SparsePro was consistent for all frequently used PIP thresholds 261 (Figure 2C) although FINEMAP and SuSiE sometimes have a slightly higher recall. 262 Furthermore, SparsePro conferred not only higher fine-mapping precision, but also higher 263 computational efficiency. In our simulation, it took only an hour to fine-map chromosome 22, 264 which was 6.5 times faster than FINEMAP and 3 times faster than SuSiE (Figure 2D and Sup-265 plementary Table S3). 266

3.2 Fine-mapped SNPs by SparsePro are more enriched in tissue-specific eQTL and confer higher trait heritability

268

We performed GWAS in the UK Biobank [1] for five functional biomarkers: FEV1-FVC ratio 269 (lung function), estimated glomerular filtration rate (kidney function), pulse rate (heart function), 270 total protein (liver function) and blood glucose level (pancreatic islet function). Genome-wide 271 fine-mapping of five functional biomarkers based on the UK Biobank population using Sparse-272 Pro identified multiple potentially causal variants (Supplementary Table S4). To assess bio-273 logical relevance of the fine-mapping results, we estimated the relative enrichment of causal 274 signals in tissue-specific eQTL for each trait (Materials and Methods). We found that the fine-275 mapped SNPs were significantly enriched in tissue-specific eQTL for all five biomarkers, while results based on SparsePro-/+ showed the strongest enrichment (Figure 3A). For example, 277 for total protein, the fine-mapped SNPs determined by SparsePro- were 4.00-fold (95% CI: 3.25-4.92) more likely to be liver-specific eQTL than non-fine-mapped SNPs, compared to a 1.54-fold (95% CI: 1.35-1.75) enrichment based on fine-mapped SNPs by SuSiE. While SuSiE 280 was substantially improved by functional priors derived from PolyFun with a 2.20-fold (95% CI: 28 1.97-2.45) enrichment, the fine-mapped SNPs by SparsePro+ exhibited the highest biological relevance, being 4.06-fold (95% CI: 3.31-4.97) more likely to be liver-specific eQTL. 283 Moreover, at most PIP thresholds, the SNPs fine-mapped by SparsePro- explained a higher 284 proportion of phenotypic variance based on all UK Biobank subjects (**Methods**) compared to 285

the same number of the most likely causal SNPs identified by SuSiE (**Figure** 3B and **Sup-**plementary Table S5). With the functional annotations (**Supplementary Table** S5), the finemapped SNPs by SparsePro+ consistently achieved a higher SNP heritability for estimated
glomerular filtration rate, FEV1-FVC ratio, as well as total protein compared to the PolyFuninformed SuSiE; although for glucose and pulse rate, PolyFun-informed SuSiE was able to
identify SNPs with a slightly higher predictive performance at certain PIP thresholds (**Figure** 3C
and **Supplementary Table** S6).

3.3 Pleiotropic effects of SNPs rs1260326 and rs5742915 on the functions of multiple vital organs

294

Overall, we observed considerable polygenicity for the five biomarkers of the vital organs (**Figure** 4A). 295 Interestingly, at the PIP threshold of 0.80, we found two potentially causal variants for three of 296 the five biomarkers. Specifically, SNP rs1260326 (Figure 4B), a missense variant (Leu446Pro) 297 in gene GCKR, was fine-mapped for glomerular filtration rate (PIP = 1.000), blood glucose level 298 (PIP = 0.998), pulse rate (PIP = 0.823) and total protein level (PIP = 1.000). Notably, this spe-299 cific variant has been found to be significantly associated with a wide variety of glycemic traits 300 [36] and other quantitative traits for metabolic syndromes and comorbidities [37, 38], and has 301 been implicated in the functions of liver and other vital organs [39–41]. 302 Another SNP, rs5742915 (Figure 4C), a missense variant (Phe645Leu) in gene PML was 303 fine-mapped for FEV1-FVC ratio (PIP = 0.858), pulse rate (PIP = 1.000) and total protein level 304 (PIP = 0.987). This variant has also been associated with other quantitative biomarkers of poly-305 genic traits featuring development and metabolism, including birth weight [42], height [43], appendicular lean mass [44], and age at menarche [45]. These findings, along with other SNPs 307 exhibiting pleiotropic effects at somewhat lower PIP thresholds (Supplementary Table S4) presented promising genetic targets for experimental validations in a larger effort towards under-309 standing the mechanisms of genetic coordination among vital organs.

4 Discussion

338

Accurately identifying trait-determining and disease-causing variants is fundamental in genetics and particularly important for appropriately interpreting GWAS results [5, 8]. In this work, we developed SparsePro, an efficient fine-mapping method to help prioritize causal variants for complex traits, possibly with prior functional information. Through genome-wide simulations, we 315 showed that SparsePro was highly accurate and computationally efficient compared to existing 316 methods. By fine-mapping genetic associations with five biomarkers for vital organ functions, 317 we demonstrated that SparsePro identified candidate variants that were biologically relevant, 318 including two variants with pleiotropic effects, which might indicate genetically encoded coordi-319 nation among vital organs. 320 Compared to the existing methods, SparsePro has three important features. First of all, we 321 use an efficient variational inference algorithm to approximate the posterior distribution of the 322 causal variant indicators instead of exhaustively searching through all possible causal config-323 urations or performing stepwise regression. As a result, SparsePro can be significantly faster 324 than the existing fine-mapping methods, such as FINEMAP [12], and is more than twice as 325 fast as SuSiE [13], which is a similar variable selection framework but implements an itera-326 tive Bayesian stepwise selection procedure. The substantially improved computational effi-327 ciency enables statistical fine-mapping of large chunks of the genome instead of analyzing 328 genetic associations on a per-locus basis as in most existing follow-up studies of GWASs. In 329 our simulation studies, compared to locus-wise fine-mapping based on COJO-identified lead SNPs, such a genome-wide fine-mapping requires neither a pre-specified p-value threshold 331 (e.g. $p < 5 imes 10^{-8}$) for determining candidate loci nor an arbitrary number of causal effects per 332 locus. If functional annotations are available, the estimation of functional enrichment may also be more robust by including more variants with little additional computational overhead. 334 Second, we utilize a paired mean field variational family, where the causal effect and the ca-335 sual indicator are coupled in the variational distribution. This ensures that our approximation 336 matches closely with the true posterior distribution of the causal variant indicators [18]. As a 337

result, SparsePro yielded better-calibrated PIPs compared to existing fine-mapping methods.

Third, given GWAS summary statistics, we provide estimates for hyperparameters including τ_y and τ_β that are reasonable in the context of polygenic trait genetics. Consequently, at several commonly used PIP thresholds for defining causal variants, SparsePro showed improved control of false positives, demonstrated higher precision in identifying causal variants in simulation and obtained stronger enrichment for tissue-specific eQTL in real data application.

339

340

34

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

364

365

366

Last, we propose and implement a probabilistic model that coherently integrates statistical evidence and functional prior information. The key difference between SparsePro+ and other methods that leverage functional priors, such as PolyFun [16] and PAINTOR [14], is that each annotation is tested for its relevance with the trait of interest before being used to derive the priors in our model. Therefore, functional annotations serve as complementary evidence when statistical evidence is not sufficient to discern causal variants. Based on our results, it seems that this approach distills better prior information from the functional annotations compared to the aforementioned methods.

We note that SparsePro can be further improved with the following future directions. First, SparsePro generally requires that the supplied LD reference panel matches well with that of the GWAS study population to guarantee proper convergence. While we advocate the public availability of the in-sample LD information along with the GWAS summary statistics, a more robust model is needed to account for mismatched LD information. Second, SparsePro currently supports only binary annotations while compatibility with continuous annotations is also desirable. Last, the current variational expectation-maximization scheme might not accurately estimate the joint enrichment of highly correlated annotations. Performing variable selection beforehand or effectively aggregating enrichment estimates may enable the inclusion of multiple correlated informative annotations, such as cell type-specific annotations to further improve the utility of SparsePro.

In summary, SparsePro is an efficient genome-wide fine-mapping method with the ability of 363 integrate functional annotations. We envision its wide utility in understanding the genetic architecture of complex traits, identifying target genes, and increasing the yield of functional followup studies of GWASs.

5 Figure Legends

Figure 1. SparsePro overview. The data generating process of SparsePro is depicted in a plate model with shaded nodes represent observed variables and unshaded nodes represent 369 latent variables. The trait y is generated from K causal effects, where the k-th causal effect size $\beta_k \sim \mathcal{N}(0, \tau_{\beta_k})$. We use a sparse projection $\mathbf{s}_k \sim Multinomial(1, \hat{\boldsymbol{\pi}})$ of genotype to indicate 371 causal variant for the k-th effect. Given the causal effect sizes and sparse indicators of causal 372 variants, the target trait y_i for individual i follows a normal distribution $y_i \sim \mathcal{N}(\mathbf{X}_i \sum_k \mathbf{s}_k \beta_k, \tau_y^{-1})$. 373 To help prioritize variants with functional annotations, we assume the prior probability of being 374 causal $\hat{\pi}_q$ for the g-th variant as $\hat{\pi}_q = softmax(\mathbf{A}_q \mathbf{w})$ where \mathbf{A}_q is a $M \times 1$ functional annotation 375 vector and w is the $M \times 1$ vector of annotation enrichment coefficients. We adopt an efficient 376 variational inference algorithm to jointly estimate both causal effect sizes and sparse indicators 377 and an expectation-maximization scheme for estimating annotation enrichment coefficients w 378 as detailed in Section 2. 379

SparsePro demonstrated improved accuracy and computational efficiency in genome-380 wide simulation results. (A) Precision-Recall curves. The inset shows the area under the preci-38 sion recall curve (AUPRC) for each method. (B) Calibration of posterior inclusion probabilities 382 (PIPs). The y-axis is the mean PIPs for all SNPs considered as causal variants, correspond-383 ing to the expected precision at different PIP cutoffs. The x-axis represents the actual preci-384 sion at different PIP cutoffs. The black dashed line indicates an optimal calibration, where the 385 expected precision perfectly matches the observed precision. (C) Precision and recall rates 386 obtained at five frequently used PIP thresholds. Error bars indicate inter-quartile ranges. (D) 387 Comparison of computational time. Boxes denote inter-quartile ranges and the line inside each 388 box indicates the median running time. The color legends are displayed at the bottom of the 389 figure. 390

Figure 3. Biological relevance of fine-mapped SNPs for five biomarkers, each for a distinct vital organ. (A) Relative enrichment of causal signals in tissue-specific eQTL. Target traits and

the corresponding organs are indicated. Estimates of relative enrichment with 95% confidence 393 intervals are plotted on a logarithmic scale. (B) Comparison of the proportion of total trait vari-394 ance explained by fine-mapped SNPs between SparsePro- and SuSiE.(C) Comparison of the 395 proportion of total variance explained by fine-mapped SNPs between SparsePro+ and PolyFun 396 informed SuSiE. Fine-mapped SNPs were identified at five PIP thresholds. As a surrogate of 397 SNP heritability, the proportion of trait variance explained was obtained from multivariate linear 398 regression adjusted R^2 . In this multivariate regression, we regress the inverse normal trans-399 formed trait residuals against all fine-mapped SNPs after adjusting for covariate effects. We se-400 lected the same number of top-ranked SNPs for each method separately at each PIP threshold 401 (Materials and Methods). 402

Figure 4. Fine-mapping genetic associations for five functional biomarkers of vital organs. (A) lllustration of genome-wide distribution of fine-mapped SNPs on 22 chromosomes. SNPs with a posterior inclusion probability > 0.80 were indicated as colored solid circles. Two loci with potential pleiotropic effects on four and three vital organ biomarkers respectively were high-lighted by red dashed rectangles. Locus zoom plots were presented for these two loci: (B) locus with fine-mapped SNP rs1260326. and (C) locus with fine-mapped SNP rs5742915. SNPs in a ± 500 kb window are included, colored by r^2 with the corresponding fine-mapped SNP.




Figure 1: SparsePro overview. The data generating process of SparsePro is depicted in a plate model with shaded nodes represent observed variables and unshaded nodes represent latent variables. The trait y is generated from K causal effects, where the k-th causal effect size $\beta_k \sim \mathcal{N}(0,\tau_{\beta_k})$. We use a sparse projection $\mathbf{s}_k \sim Multinomial(1,\hat{\pi})$ of genotype to indicate causal variant for the k-th effect. Given the causal effect sizes and sparse indicators of causal variants, the target trait y_i for individual i follows a normal distribution $y_i \sim \mathcal{N}(\mathbf{X}_i \sum_k \mathbf{s}_k \beta_k, \tau_y^{-1})$. To help prioritize variants with functional annotations, we assume the prior probability of being causal $\hat{\pi}_g$ for the g-th variant as $\hat{\pi}_g = softmax(\mathbf{A}_g\mathbf{w})$ where \mathbf{A}_g is a $M \times 1$ functional annotation vector and \mathbf{w} is the $M \times 1$ vector of annotation enrichment coefficients. We adopt an efficient variational inference algorithm to jointly estimate both causal effect sizes and sparse indicators and an expectation-maximization scheme for estimating annotation enrichment coefficients \mathbf{w} as detailed in Section 2.




Figure 2: SparsePro demonstrated improved accuracy and computational efficiency in genome-wide simulation results. (A) Precision-Recall curves. The inset shows the area under the precision recall curve (AUPRC) for each method. (B) Calibration of posterior inclusion probabilities (PIPs). The y-axis is the mean PIPs for all SNPs considered as causal variants, corresponding to the expected precision at different PIP cutoffs. The x-axis represents the actual precision at different PIP cutoffs. The black dashed line indicates an optimal calibration, where the expected precision perfectly matches the observed precision. (C) Precision and recall rates obtained at five frequently used PIP thresholds. Error bars indicate inter-quartile ranges. (D) Comparison of computational time. Boxes denote inter-quartile ranges and the line inside each box indicates the median running time. The color legends are displayed at the bottom of the figure.




Figure 3: Biological relevance of fine-mapped SNPs for five biomarkers, each for a distinct vital organ. (A) Relative enrichment of causal signals in tissue-specific eQTL. Target traits and the corresponding organs are indicated. Estimates of relative enrichment with 95% confidence intervals are plotted on a logarithmic scale. (B) Comparison of the proportion of total trait variance explained by fine-mapped SNPs between SparsePro- and SuSiE.(C) Comparison of the proportion of total variance explained by fine-mapped SNPs between SparsePro+ and PolyFun informed SuSiE. Fine-mapped SNPs were identified at five PIP thresholds. As a surrogate of SNP heritability, the proportion of trait variance explained was obtained from multivariate linear regression adjusted \mathbb{R}^2 . In this multivariate regression, we regress the inverse normal transformed trait residuals against all fine-mapped SNPs after adjusting for covariate effects. We selected the same number of top-ranked SNPs for each method separately at each PIP threshold (Materials and Methods).




Figure 4: Fine-mapping genetic associations for five functional biomarkers of vital organs. (A) Illustration of genome-wide distribution of fine-mapped SNPs on 22 chromosomes. SNPs with a posterior inclusion probability > 0.80 were indicated as colored solid circles. Two loci with potential pleiotropic effects on four and three vital organ biomarkers respectively were highlighted by red dashed rectangles. Locus zoom plots were presented for these two loci: (B) locus with fine-mapped SNP rs1260326. and (C) locus with fine-mapped SNP rs5742915. SNPs in a ± 500 kb window are included, colored by r^2 with the corresponding fine-mapped SNP.

6 Acknowledgements

YL is supported by Natural Sciences and Engineering Research Council (NSERC) Discovery
Grant (RGPIN-2019-0621), Fonds de recherche Nature et technologies (FRQNT) New Career (NC-268592), and Canada First Research Excellence Fund Healthy Brains for Healthy Life
(HBHL) initiative New Investigator start-up award (G249591). This study has been conducted
using UK Biobank Resources under Application Number 45551. This study was enabled, in
part, by support from Calcul Québec and Compute Canada. WZ has been supported by a doctoral training fellowship from the Healthy Brains, Healthy Lives Program, funded by the Canada
First Research Excellence Fund (CFREF), Quebec's Ministère de l'Économie et de l'Innovation
(MEI), and the Fonds de recherche du Québec (FRQS, FRQSC and FRQNT).H.S.N. holds a
Canada Research Chair funded by the Canadian Institutes of Health Research.

7 Author contributions

W.Z and Y.L have conceived the study and developed the methodology. W.Z created the computational software and ran the analyses. All authors interpreted the results. W.Z. drafted the initial manuscript. H.S.N and Y.L supervised this study and revised the manuscript critically.

8 Disclosures

The authors declare no conflict of interest.

9 Data and Software Availability

SparsePro is an open-access software and publicly available at https://github.com/zhwm/
SparsePro. All simulation and plotting scripts to reproduce this study are publicly available at
https://github.com/zhwm/SparsePro_Paper. Individual-level phenotype and genotype data
from the UK Biobank are available upon successful application to its research committee. GCTA

- were downloaded from https://cnsgenomics.com/software/gcta/bin/gcta_1.93.2beta.zip.
- FINEAMP were downloaded from http://www.christianbenner.com/finemap_v1.4_x86_64.
- tgz. SuSiE (version 0.11.42) were installed from CRAN. PolyFun were installed from https:
- //github.com/omerwe/polyfun. UK Biobank LD information was downloaded from https://
- alkesgroup.broadinstitute.org/UKBB_LD/. Tissue-specific eQTL were obtained from https:
- //storage.googleapis.com/gtex_analysis_v8/single_tissue_qtl_data/GTEx_Analysis_
- 438 v8_eQTL_EUR.tar.

References

- 1. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–209 (2018).
- Canela-Xandri, O., Rawlik, K. & Tenesa, A. An atlas of genetic associations in UK Biobank.
 Nature genetics 50, 1593–1599 (2018).
- 3. Loh, P.-R., Kichaev, G., Gazal, S., Schoech, A. P. & Price, A. L. Mixed-model association for biobank-scale datasets. *Nature genetics* **50**, 906–908 (2018).
- 4. Visscher, P. M. *et al.* 10 years of GWAS discovery: biology, function, and translation. *The American Journal of Human Genetics* **101**, 5–22 (2017).
- 5. Schaid, D. J., Chen, W. & Larson, N. B. From genome-wide associations to candidate causal variants by statistical fine-mapping. *Nature Reviews Genetics* **19**, 491–504 (2018).
- 6. Stranger, B. E., Stahl, E. A. & Raj, T. Progress and promise of genome-wide association studies for human complex trait genetics. *Genetics* **187**, 367–383 (2011).
- 7. Benner, C. *et al.* Prospects of fine-mapping trait-associated genomic regions by using summary statistics from genome-wide association studies. *The American Journal of Human Genetics* **101**, 539–551 (2017).
- 8. Spain, S. L. & Barrett, J. C. Strategies for fine-mapping complex traits. *Human molecular* genetics **24**, R111–R119 (2015).

- 9. Servin, B. & Stephens, M. Imputation-based analysis of association studies: candidate regions and quantitative traits. *PLoS genetics* **3**, e114 (2007).
- Hormozdiari, F., Kostem, E., Kang, E. Y., Pasaniuc, B. & Eskin, E. Identifying causal variants at loci with multiple signals of association. *Genetics* **198**, 497–508 (2014).
- 11. Chen, W. *et al.* Fine mapping causal variants with an approximate Bayesian method using marginal test statistics. *Genetics* **200**, 719–736 (2015).
- Head 12. Benner, C. *et al.* FINEMAP: efficient variable selection using summary data from genomewide association studies. *Bioinformatics* **32**, 1493–1501 (2016).
- Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable
 selection in regression, with application to genetic fine mapping. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)* 82, 1273–1300 (2020).
- ⁴⁶⁸ 14. Kichaev, G. *et al.* Integrating functional data to prioritize causal variants in statistical fine-⁴⁶⁹ mapping studies. *PLoS genetics* **10**, e1004722 (2014).
- Li, Y. & Kellis, M. Joint Bayesian inference of risk variants and tissue-specific epigenomic enrichments across multiple complex human diseases. *Nucleic acids research* **44**, e144–e144 (2016).
- Weissbrod, O. *et al.* Functionally informed fine-mapping and polygenic localization of complex trait heritability. *Nature Genetics* **52**, 1355–1363 (2020).
- ⁴⁷⁵ 17. Finucane, H. K. *et al.* Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. *Nature genetics* **50**, 621–629 (2018).
- Titsias, M. & Lázaro-Gredilla, M. Spike and slab variational inference for multi-task and multiple kernel learning. *Advances in neural information processing systems* **24**, 2339–2347 (2011).
- 19. Kichaev, G. *et al.* Improved methods for multi-trait fine mapping of pleiotropic risk loci.
 Bioinformatics 33, 248–255 (2017).
- Blei, D. M., Kucukelbir, A. & McAuliffe, J. D. Variational inference: A review for statisticians.

 Journal of the American statistical Association 112, 859–877 (2017).

- Woolf, B. The log likelihood ratio test (the G-test). *Annals of human genetics* **21**, 397–409 (1957).
- Shi, H., Kichaev, G. & Pasaniuc, B. Contrasting the genetic architecture of 30 complex traits from summary association data. *The American Journal of Human Genetics* **99,** 139–153 (2016).
- Lindblad-Toh, K. *et al.* A high-resolution map of human evolutionary constraint using 29 mammals. *Nature* **478**, 476–482 (2011).
- Trynka, G. *et al.* Chromatin marks identify critical cell types for fine mapping complex trait variants. *Nature genetics* **45**, 124–130 (2013).
- ⁴⁹³ 25. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic acids research* **38**, e164–e164 (2010).
- Hnisz, D. *et al.* Super-enhancers in the control of cell identity and disease. *Cell* **155**, 934–946 947 (2013).
- Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. *The American Journal of Human Genetics* **88,** 76–82 (2011).
- ⁴⁹⁹ 28. Jiang, L. *et al.* A resource-efficient tool for mixed model association analysis of large-⁵⁰⁰ scale data. *Nature genetics* **51**, 1749–1755 (2019).
- 501 29. Hoffman, M. M. *et al.* Integrative annotation of chromatin elements from ENCODE data.

 502 *Nucleic acids research* **41**, 827–841 (2013).
- 30. Villar, D. *et al.* Enhancer evolution across 20 mammalian species. *Cell* **160**, 554–566
 (2015).
- yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nature genetics* **44**, 369–375 (2012).
- 507 32. Lonsdale, J. *et al.* The genotype-tissue expression (GTEx) project. *Nature genetics* **45**, 508 580–585 (2013).
- 509 33. Consortium, G. *et al.* The GTEx Consortium atlas of genetic regulatory effects across hu-510 man tissues. *Science* **369**, 1318–1330 (2020).

- Wolfe, D., Dudek, S., Ritchie, M. D. & Pendergrass, S. A. Visualizing genomic information across chromosomes with PhenoGram. *BioData mining* **6,** 1–12 (2013).
- 513 35. Pruim, R. J. *et al.* LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics* **26**, 2336–2337 (2010).
- 515 36. Chen, J. *et al.* The trans-ancestral genomic architecture of glycemic traits. *Nature genet-*516 *ics* **53**, 840–860 (2021).
- 517 37. Huang, L. O. *et al.* Genome-wide discovery of genetic loci that uncouple excess adiposity 518 from its comorbidities. *Nature Metabolism* **3**, 228–243 (2021).
- 519 38. Vuckovic, D. *et al.* The polygenic and monogenic basis of blood traits and diseases. *Cell* 520 **182,** 1214–1231 (2020).
- 521 39. Chen, V. L. *et al.* Genome-wide association study of serum liver enzymes implicates di-522 verse metabolic and liver pathology. *Nature communications* **12**, 1–13 (2021).
- 523 40. Pazoki, R. *et al.* Genetic analysis in European ancestry individuals identifies 517 loci as-524 sociated with liver enzymes. *Nature communications* **12**, 1–12 (2021).
- Bell, S. *et al.* A genome-wide meta-analysis yields 46 new loci associating with biomarkers of iron homeostasis. *Communications biology* **4**, 1–14 (2021).
- ⁵²⁷ 42. Warrington, N. M. *et al.* Maternal and fetal genetic effects on birth weight and their rele-⁵²⁸ vance to cardio-metabolic risk factors. *Nature genetics* **51**, 804–814 (2019).
- 529 43. Wood, A. R. *et al.* Defining the role of common variation in the genomic and biological ar-530 chitecture of adult human height. *Nature genetics* **46**, 1173–1186 (2014).
- ⁵³¹ 44. Pei, Y.-F. *et al.* The genetic architecture of appendicular lean mass characterized by asso⁵³² ciation analysis in the UK Biobank study. *Communications biology* **3**, 1–13 (2020).
- 533 45. Kichaev, G. *et al.* Leveraging polygenic functional enrichment to improve GWAS power.

 534 *The American Journal of Human Genetics* **104,** 65–75 (2019).

SparsePro Supplementary Information

Wenmin Zhang¹, Hamed Najafabadi^{1,2,3}, Yue Li^{1,4,*}

¹Quantitative Life Sciences, McGill University, Montreal, Canada

²Department of Human Genetics, McGill University, Montreal, Canada

³McGill Genome Centre, Montreal, Canada

⁴School of Computer Science, McGill University

*Correspondence: yueli@cs.mcgill.ca

1 Supplementary Notes

1.1 SparsePro is not sensitive to hyperparameter K

The number of causal effects K is an important hyperparameter in statistical fine-mapping. In methods that exhaustively search through causal configurations, the computation time increases combinatorially with K since the number of candidate causal configurations also grows combinatorially. In contrast, in SparsePro, the computation time increases linearly with K. In practice, most of the computation time is spent on loading LD information, thus the computation time varies only slightly with $K \in \{5,7,9,11\}$. The output of SparsePro is not sensitive to the choice of K as long as K is greater than or equal to the actual number of causal effects. In our simulation studies, we found that with K = 7, 9, or 11, the resulting PIPs were extremely highly correlated with those based on K = 5, and the overal AUPRC metrics were also highly consistent (**Supplementary Table S2**).

1.2 Modified HESS estimates for hyperparameters au_y and au_{eta}

Local heritability estimates are useful in setting hyperparameters for SparsePro. Shi et al. [22] provided an unbiased estimator for local heritability estimation based on summary statistics:

$$\hat{h}_g = \frac{N\hat{\boldsymbol{\beta}}^T \mathbf{R}^{-1}\hat{\boldsymbol{\beta}} - P}{N - P}$$

where \mathbf{R} is the LD matrix, $\hat{\boldsymbol{\beta}}$ is GWAS summary effect size, N is the sample size in the GWAS and P is the number of SNPs considered in a locus. However, this estimate requires that when generating summary statistics, both genotypes and phenotypes should be standardized to have zero mean and unit variance. Since summary statistics generated by some GWAS pipelines do not specifically standardize the genotypes and phenotypes, we modified the HESS estimator to account for the non-unit variance:

$$\hat{h}_g = \frac{(\hat{\boldsymbol{\beta}} \circ \mathbf{v})^T (\mathbf{X}^\top \mathbf{X})^{-1} (\hat{\boldsymbol{\beta}} \circ \mathbf{v}) - var(\mathbf{y}) P}{var(\mathbf{y})(N - P)}$$

where \circ represents element-wise multiplication and \mathbf{v} is a $P \times 1$ vector: $v_p = \mathbf{X}_p^{\top} \mathbf{X}_p$ for the p-th SNP with genotype vector \mathbf{X}_p . This estimate can be adapted to directly operate on summary statistics as explained in **Materials and Methods**.

1.3 Full derivation of variational EM algorithm:

As has been described in **Materials and Methods**, based on the data generative process, for the k-th causal effect, we have:

$$\mathbf{s}_{k} \sim Multinomial(1, \tilde{\boldsymbol{\pi}})$$
$$\beta_{k} \sim \mathcal{N}(0, \tau_{\beta_{k}}^{-1})$$
$$\mathbf{y} = X \sum_{k} \mathbf{s}_{k} \beta_{k} + \boldsymbol{\epsilon}$$

with $\epsilon_i \sim N(0, \tau_y^{-1})$. Therefore, we have the joint probability:

$$p(\mathbf{y}, \mathbf{S}, \boldsymbol{\beta} | \mathbf{X}, \tilde{\boldsymbol{\pi}}, \tau_{\beta}, \tau_{y}) = p(\mathbf{y} | \mathbf{X}, \mathbf{S}, \boldsymbol{\beta}, \tau_{y}) \prod_{k} p(\beta_{k} | \tau_{\beta_{k}}) \prod_{k} p(\mathbf{s}_{k} | \tilde{\boldsymbol{\pi}})$$
(4)

The goal of fine-mapping is to infer the posterior probability, and in particular, of the sparse projection S (from here we make the dependency on hyperparameters implicit for the ease of notation):

$$p(\mathbf{S}, \boldsymbol{\beta}|\mathbf{y}, \mathbf{X}) = \frac{p(\mathbf{y}, \mathbf{S}, \boldsymbol{\beta}|\mathbf{X})}{p(\mathbf{y}|\mathbf{X})}$$

We use a paired mean field factorized [18] variational family $q(S, \beta)$ to approximate the pos-561 terior: 562

$$q(\mathbf{S}, \boldsymbol{\beta}) = \prod_{k} q(\mathbf{s}_k, \beta_k) = \prod_{k} q(\mathbf{s}_k) q(\beta_k | \mathbf{s}_k)$$

Note that in this variational family, we do not specify the form of the distribution; rather, we 563 only specify the dependency of β_k on s_k and that all K causal effects are independent of each other. Also, the form of the variational family does not depend on any observed data. To better approximate the posterior distribution with members of the variational family, we 566 aim to minimize the KL divergence between the posterior distribution and the proposed varia-

tional distribution, which is equivalent to maximizing the ELBO [20]: 568

567

$$ELBO = E_{q(\mathbf{S}, \boldsymbol{\beta})}[\log p(\mathbf{y}, \mathbf{S}, \boldsymbol{\beta} | \mathbf{X})] - E_{q(\mathbf{S}, \boldsymbol{\beta})}[\log q(\mathbf{S}, \boldsymbol{\beta})]$$

To maximize the above ELBO, the following requirement should be satisfied for each k:

$$\log q(\mathbf{s}_k, \beta_k) = E_{q(\mathbf{S}_{\backslash k}, \boldsymbol{\beta}_{\backslash k})}[(\mathbf{y}, \mathbf{S}, \boldsymbol{\beta} | \mathbf{X})]$$

where $E_{q(\mathbf{S}_{\backslash k}, \mathbf{\beta}_{\backslash k})}$ is the expectation with respect to the variational distribution excluding the k-th

component. With the joint probability provided in Equation (4) we have

$$\log p(\mathbf{y}, \mathbf{S}, \boldsymbol{\beta} | \mathbf{X}) = \log p(\mathbf{y} | \mathbf{X}, \mathbf{S}, \boldsymbol{\beta}) + \sum_{k} \log p(\beta_k | \tau_{\beta_k}) + \sum_{k} (\mathbf{s}_k | \tilde{\boldsymbol{\pi}})$$

$$= \frac{N}{2} \log \frac{\tau_y}{2\pi} - \frac{\tau_y}{2} (\mathbf{y} - \mathbf{X} (\sum_{k} \mathbf{s}_k \beta_k))^{\top} (\mathbf{y} - \mathbf{X} (\sum_{k} \mathbf{s}_k \beta_k))$$

$$+ \sum_{k} (\frac{1}{2} \log \frac{\tau_{\beta_k}}{2\pi} - \frac{\tau_{\beta_k}}{2} \beta_k^2) + \sum_{k} \sum_{g} s_{kg} \log \tilde{\pi}_g$$

Taking expectation with respect to the variational distribution excluding the k-th component and plugging in $s_{kg}=1$ and $\mathbf{s}_{k\setminus g}=\mathbf{0}$ for all SNPs excluding the g-th SNP, we can obtain the joint distribution of the k-th effect as:

$$\log q(s_{kg} = 1, \mathbf{s}_{k \setminus g} = \mathbf{0}, \beta_k) = const - \frac{\tau_{\beta_k}}{2} \beta_k^2 - \frac{\tau_y}{2} \mathbf{X}_g^\top \mathbf{X}_g \beta_k^2 + \tau_y \beta_k \mathbf{X}_g^\top (\mathbf{y} - X \tilde{\boldsymbol{\beta}}_{\setminus k}) + log \tilde{\pi}_g$$
 (5)

572 where

$$\tilde{\boldsymbol{\beta}}_{\backslash k} = E_{q(\mathbf{S}_{\backslash k}, \boldsymbol{\beta}_{\backslash k})}[\sum_{k' \neq k} \mathbf{s}_k \beta_k] = \sum_{k' \neq k} \gamma_{k'}^* \circ \mu_{k'}^*$$

We recognize that

$$q(\beta_k|s_{kq=1},\mathbf{s}_{k\setminus q}=\mathbf{0}) \sim \mathcal{N}(\mu_{kq}^*,\tau_{kq}^*)$$

By matching sufficient statistics for this normal distribution, we can obtain the following variational parameters for updates:

$$\tau_{kg}^* = \tau_y \mathbf{X}_g^{\top} \mathbf{X}_g + \tau_{\beta_k}$$
$$\mu_{kg}^* = \frac{\tau_y}{\tau_{kg}^*} \mathbf{X}_g^{\top} (\mathbf{y} - X \tilde{\beta}_{\backslash k})$$

By integrating out β_k in Equation (5), we obtain that

$$\log q(s_{kg} = 1, \mathbf{s}_{k \setminus g} = \mathbf{0}) = \log \tilde{\pi}_g - \frac{1}{2} \log \frac{\tau_{kg}^*}{2\pi} + \frac{1}{2} \tau_{kg}^* \mu_{kg}^{*2} + const$$

Therefore, the posterior probability of the g-th SNP being causal in the k-th effect can be estimated as:

$$\gamma_{kg}^* := q(s_{kg} = 1, \mathbf{s}_{k \setminus g} = \mathbf{0}) = softmax(\log \tilde{\pi}_g - \frac{1}{2} \log \frac{\tau_{kg}^*}{2\pi} + \frac{1}{2} \tau_{kg}^* \mu_{kg}^{*2})$$

This completes the variational expectation step in our inference algorithm. When functional annotations are available, we use the following maximization step to integrate relevant annotations. After the expectation step, we have that

$$\begin{split} ELBO &= const + \sum_{k,g} \gamma_{k,g}^* \log \tilde{\pi}_g \\ &= const + \sum_{k,g} \gamma_{k,g}^* \log \frac{\exp(\mathbf{A}_g \mathbf{w})}{\sum_g \exp(\mathbf{A}_g \mathbf{w})} \\ &= const + \sum_{k,g} \gamma_{k,g}^* [\mathbf{A}_g \mathbf{w} - \log(\sum_g \exp(\mathbf{A}_g \mathbf{w}))] \end{split}$$

To maximize ELBO with respect to the relative enrichment of the m-th candidate annotation,

we take partial derivatives of ELBO with respect to w_m and set it to 0 to solve for w_m :

$$\begin{split} \frac{\partial ELBO}{\partial w_m} &= \sum_{k,g} \gamma_{k,g}^* [A_{gm} - \frac{\sum_g A_{gm} \exp(\mathbf{A}_g \mathbf{w}))}{\sum_g \exp(\mathbf{A}_g \mathbf{w}))}] \\ &= \sum_{k,g} \gamma_{k,g}^* [A_{gm} - \frac{\sum_g A_{gm} \exp(A_{gm} w_m) \exp(\sum_{m' \neq m} A_{gm'} w_{m'}))}{\sum_g \exp(A_{gm} w_m) \exp(\sum_{m' \neq m} A_{gm'} w_{m'}))}] \\ &= \sum_{k,g} \gamma_{k,g}^* [A_{gm} - \frac{\sum_g A_{gm} \exp(A_{gm} w_m) softmax(\sum_{m' \neq m} A_{gm'} w_{m'})}{\sum_g \exp(A_{gm} w_m) softmax(\sum_{m' \neq m} A_{gm'} w_{m'})}] \\ &= \sum_{k,g} [A_{gm} = 1] \gamma_{kg}^* \\ &- \sum_{k,g} \gamma_{kg}^* \frac{e^{w_m} \sum_g [A_{gm} = 1] softmax(\sum_{m' \neq m} A_{gm'} w_{m'})}{\sum_g \exp(A_{gm} w_m) softmax(\sum_{m' \neq m} A_{gm'} w_{m'})} \\ &= \sum_{k,g} \gamma_{kg}^* \frac{e^{w_m} \sum_g [A_{gm} = 1] softmax(\sum_{m' \neq m} A_{gm'} w_{m'})}{\sum_g [A_{gm} = 0] softmax(\sum_{m' \neq m} A_{gm'} w_{m'})} \\ &= r_1 - (r_1 + r_0) \frac{k_1 e^{w_m}}{k_1 e^{w_m} + k_0} \\ &= 0 \end{split}$$

where

$$k_1 = \sum_{g} [A_{gm} = 1] softmax \left(\sum_{m' \neq m} A_{gm'} w_{m'} \right)$$

$$k_0 = \sum_{g} [A_{gm} = 0] softmax \left(\sum_{m' \neq m} A_{gm'} w_{m'} \right)$$

$$r_1 = \sum_{k,g} [A_{gm} = 1] \gamma_{kg}^*$$

$$r_0 = \sum_{k,g} [A_{gm} = 0] \gamma_{kg}^*$$

We then obtain:

$$\frac{k_1 e^{w_m}}{k_1 e^{w_m} + k_0} = \frac{r_1}{r_1 + r_0}$$

and solve for:

$$w_m = \log\left(\frac{r_1/r_0}{k_1/k_0}\right)$$

Notably, this estimate is analogous to a relative risk estimate in a 2×2 contigency table. Suppose we consider one annotation, then k_1 corresponds to the number of variants with this specific annotation while k_0 corresponds to the number of variants without the annotation. Meanwhile, r_0 corresponds to the sum of posterior probability for variants with the annotation while r_1 corresponds to the sum of posterior probability for variants without the annotation.

Similarly, the standard error of this estimate can be calculated based on the standard error of a relative risk:

$$se(\hat{w}_m) = \sqrt{\frac{1}{r_1} + \frac{1}{r_0} - \frac{1}{k_1} - \frac{1}{k_0}}$$

Finally, we can evaluate the statistical significance of enrichment with the log likelihood ratio test (G-test) [21].

2 Supplementary Table Legends

- Supplementary Table S1 Relative enrichment of functional priors in simulation studies.
- Supplementary Table S2 Comparison of fine-mapping results based on different hyperparameter settings of the number of causal effects K.
- Supplementary Table S3 Details of computation time by each method.
- Supplementary Table S4 Fine-mapping results for five functional biomarkers based on the UK Biobank, including genetic variants with a PIP > 0.1.

- Supplementary Table S5 Relative enrichment of functional annotations for five functional
- 590 biomarkers.
- Supplementary Table S6 Comparison of fine-mapped SNP heritability for five functional
- 592 biomarkers.